---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-22-000006"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T22:03:06.877150+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics reports FY2021 net loss $125.6M; cash $209.8M, runway into 2024

## Summary
- Net loss FY2021 $125.6M vs $67.3M YoY; Q4 loss $25.9M vs $22.6M.
- Cash $209.8M at Dec 31, 2021 (down from $315.1M); sufficient to fund operations into 2024.
- R&D spend $96.8M in 2021 (vs $48.2M); G&A $30.0M (vs $21.4M).
- FDA allowed IND for BDTX-1535; Phase 1 study initiated for GBM and NSCLC with CNS metastases.
- Appointed Elizabeth Montgomery as Chief People Officer, bringing nearly 20 years HR experience in life sciences.

## SEC filing metadata
- accession: 0001701541-22-000006
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000006/0001701541-22-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000006/bdtx-20220317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-22-000006
- JSON: https://secwatch.observer/filing/0001701541-22-000006.json
- Plain text: https://secwatch.observer/filing/0001701541-22-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.